Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Cash (2016 - 2025)

Historic Change in Cash for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to -$4.2 million.

  • Protalix BioTherapeutics' Change in Cash fell 20593.52% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year decrease of 29657.19%. This contributed to the annual value of -$3.9 million for FY2024, which is 15938.99% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Change in Cash stood at -$4.2 million, which was down 20593.52% from -$1.6 million recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Change in Cash high stood at $28.3 million for Q4 2021, and its period low was -$27.8 million during Q3 2023.
  • Moreover, its 5-year median value for Change in Cash was -$302000.0 (2025), whereas its average is -$243052.6.
  • Per our database at Business Quant, Protalix BioTherapeutics' Change in Cash surged by 49896.45% in 2021 and then plummeted by 151194.89% in 2022.
  • Protalix BioTherapeutics' Change in Cash (Quarter) stood at $28.3 million in 2021, then tumbled by 77.45% to $6.4 million in 2022, then tumbled by 49.52% to $3.2 million in 2023, then crashed by 337.1% to -$7.6 million in 2024, then skyrocketed by 44.46% to -$4.2 million in 2025.
  • Its last three reported values are -$4.2 million in Q3 2025, -$1.6 million for Q2 2025, and -$302000.0 during Q1 2025.